{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:47:16Z","timestamp":1790772436429,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:00:00Z","timestamp":1671062400000},"content-version":"am","delay-in-days":440,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.bulcan.2021.06.003","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T11:33:03Z","timestamp":1639567983000},"page":"S181-S194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"S","title":["Anticorps bisp\u00e9cifiques ciblant CD3\u00a0en oncologie solide et onco-h\u00e9matologie"],"prefix":"10.1016","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9934-5719","authenticated-orcid":false,"given":"H\u00e9l\u00e8ne","family":"Vanacker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4455-557X","authenticated-orcid":false,"given":"Armelle","family":"Vinceneux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8450-4593","authenticated-orcid":false,"given":"Emmanuelle","family":"Nicolas-Virelizier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Brahmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3857-1688","authenticated-orcid":false,"given":"Philippe A.","family":"Cassier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.bulcan.2021.06.003_bib0155","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.bulcan.2021.06.003_bib0160","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1158\/2159-8290.CD-20-0672","article-title":"Somatic HLA Class I loss is a widespread mechanism of immune evasion which refines the use of tumor mutational burden as a biomarker of checkpoint inhibitor response","volume":"11","author":"Montesion","year":"2021","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.bulcan.2021.06.003_bib0165","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"19","key":"10.1016\/j.bulcan.2021.06.003_bib0170","doi-asserted-by":"crossref","first-page":"28059","DOI":"10.18632\/oncotarget.8574","article-title":"Immune-mediated liver injury of the cancer therapeutic antibody catumaxomab targeting EpCAM, CD3\u00a0and Fc\u03b3 receptors","volume":"7","author":"Borlak","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.bulcan.2021.06.003_bib0175","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41416-018-0150-6","article-title":"Randomised phase II trial to investigate catumaxomab (anti-EpCAM\u00d7anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer","volume":"119","author":"Kn\u00f6dler","year":"2018","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2021.06.003_bib0180","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1038\/s41598-017-02823-9","article-title":"Efficient generation of bispecific murine antibodies for pre-clinical investigations in syngeneic rodent models","volume":"7","author":"Labrijn","year":"2017","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.bulcan.2021.06.003_bib0185","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1002\/1521-4141(200211)32:11<3102::AID-IMMU3102>3.0.CO;2-C","article-title":"Optimizing anti-CD3\u00a0affinity for effective T cell targeting against tumor cells","volume":"32","author":"Bortoletto","year":"2002","journal-title":"Eur J Immunol"},{"issue":"4","key":"10.1016\/j.bulcan.2021.06.003_bib0190","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1158\/1535-7163.MCT-17-0657","article-title":"Relative target affinities of T-Cell\u2013dependent bispecific antibodies determine biodistribution in a solid tumor mouse model","volume":"17","author":"Mandikian","year":"2018","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"10.1016\/j.bulcan.2021.06.003_bib0195","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1158\/1078-0432.CCR-18-2918","article-title":"89Zr-labeled bispecific T-cell engager AMG 211\u00a0PET shows AMG 211\u00a0accumulation in CD3-rich tissues and clear, heterogeneous tumor uptake","volume":"25","author":"Moek","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.bulcan.2021.06.003_bib0200","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1158\/1078-0432.CCR-15-1696","article-title":"A novel carcinoembryonic antigen T-Cell bispecific antibody (CEA TCB) for the treatment of solid tumors","volume":"22","author":"Bacac","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.bulcan.2021.06.003_bib0205","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.clcc.2016.07.009","article-title":"Phase 1\u00a0dose escalation study of MEDI-565, a bispecific T-Cell engager that targets human carcinoembryonic antigen, in patients with advanced gastrointestinal adenocarcinomas","volume":"15","author":"Pishvaian","year":"2016","journal-title":"Clinical Colorectal Cancer"},{"issue":"15\u00a0suppl","key":"10.1016\/j.bulcan.2021.06.003_bib0210","article-title":"Phase 1\u00a0study of pasotuxizumab (BAY 2010112), a PSMA-targeting Bispecific T cell Engager (BiTE) immunotherapy for metastatic castration-resistant prostate cancer (mCRPC)","volume":"37","author":"Hummel","year":"2019","journal-title":"JCO"},{"issue":"1","key":"10.1016\/j.bulcan.2021.06.003_bib0215","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2\u00a0study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.bulcan.2021.06.003_bib0220","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.bulcan.2021.06.003_bib0225","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","article-title":"Complete hematologic and molecular response in adult patients with relapsed\/refractory philadelphia chromosome\u2013positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study","volume":"35","author":"Martinelli","year":"2017","journal-title":"JCO"},{"issue":"36","key":"10.1016\/j.bulcan.2021.06.003_bib0230","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase I\/Phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"34","author":"von\u00a0Stackelberg","year":"2016","journal-title":"JCO"},{"issue":"3","key":"10.1016\/j.bulcan.2021.06.003_bib0235","first-page":"585","article-title":"T cell\u2013activating bispecific antibodies in cancer therapy","volume":"203","author":"Trabolsi","year":"2019","journal-title":"JI"},{"issue":"10","key":"10.1016\/j.bulcan.2021.06.003_bib0240","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1007\/s00277-020-04221-0","article-title":"Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies","volume":"99","author":"Viardot","year":"2020","journal-title":"Ann Hematol"},{"issue":"Supplement 1","key":"10.1016\/j.bulcan.2021.06.003_bib0245","article-title":"Open-label, phase 2\u00a0Study of blinatumomab after first-line rituximab-chemotherapy in adults with newly diagnosed, high-risk diffuse large B-cell lymphoma","volume":"134","author":"Katz","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bulcan.2021.06.003_bib0250","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1080\/10428194.2020.1759055","article-title":"Open-Label, phase 2\u00a0study of blinatumomab as second salvage therapy in adults with relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma","volume":"61","author":"Coyle","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"Supplement 1","key":"10.1016\/j.bulcan.2021.06.003_bib0255","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2019-123742","article-title":"Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-Cell (CAR-T) therapies, and is active in treatment through multiple lines","volume":"134","author":"Schuster","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2021.06.003_bib0260","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3389\/fimmu.2020.00501","article-title":"Bispecific antibodies for multiple myeloma: a review of targets, drugs, clinical trials, and future directions","volume":"11","author":"Caraccio","year":"2020","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.bulcan.2021.06.003_bib0265","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1200\/JCO.19.02657","article-title":"Anti-B-Cell maturation antigen BiTE molecule AMG 420\u00a0induces responses in multiple myeloma","volume":"38","author":"Topp","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.bulcan.2021.06.003_bib0270","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/d41573-020-00164-3","article-title":"Trispecific antibodies take to the clinic","volume":"19","author":"Mullard","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"26","key":"10.1016\/j.bulcan.2021.06.003_bib0275","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","article-title":"A phase 1\u00a0study of the bispecific anti-CD30\/CD16A antibody construct AFM13\u00a0in patients with relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Rothe","year":"2015","journal-title":"Blood"},{"issue":"15\u00a0suppl","key":"10.1016\/j.bulcan.2021.06.003_bib0280","article-title":"Phase 1\u00a0study of AMG 757, a half-life extended bispecific T cell engager (BiTE) antibody construct targeting DLL3, in patients with small cell lung cancer (SCLC)","volume":"37","author":"Smit M-AD","year":"2019","journal-title":"JCO"},{"issue":"22","key":"10.1016\/j.bulcan.2021.06.003_bib0285","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-20-1247","article-title":"Tebentafusp, a TCR\/Anti-CD3\u00a0bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma","volume":"26","author":"Middleton","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.bulcan.2021.06.003_bib0290","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1038\/s41467-020-16838-w","article-title":"Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody","volume":"11","author":"Geiger","year":"2020","journal-title":"Nature Commun"},{"issue":"3","key":"10.1016\/j.bulcan.2021.06.003_bib0295","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"7827","key":"10.1016\/j.bulcan.2021.06.003_bib0150","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-020-2746-2","article-title":"Functional genomic landscape of cancer-intrinsic evasion of killing by T cells","volume":"586","author":"Lawson","year":"2020","journal-title":"Nature"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455121002575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455121002575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:35:04Z","timestamp":1757792104000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455121002575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0007455121002575"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2021.06.003","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticorps bisp\u00e9cifiques ciblant CD3\u00a0en oncologie solide et onco-h\u00e9matologie","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2021.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}